Evidence map›Paper›PMID 34545605›Full record

ReviewCell biochemistry and function2021

The critical role of mesenchymal stromal/stem cell therapy in COVID-19 patients: An updated review.

Mohsen Ebrahimi, Mohammad Taha Saadati Rad, Arghavan Zebardast, Mitra Ayyasi, Golnaz Goodarzi, Sadra Samavarchi Tehrani

Abstract readReview
In one paragraph

Review in Cell biochemistry and function, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohsen EbrahimiNeonatal and Child Health Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Mohammad Taha Saadati RadPsychiatric and Behavioral Sciences Research Center, Addiction Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Arghavan ZebardastDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mitra AyyasiCritical Care Nursing, Islamic Azad University, Sari Branch, Sari, Iran.
Golnaz GoodarziDepartment of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sadra Samavarchi TehraniDepartment of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-1043-2443

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New coronavirus disease 2019 (COVID-19), as a pandemic disaster, has drawn the attention of researchers in various fields to discover suitable therapeutic approaches for the management of COVID-19 patients. Currently, there are many worries about the rapid spread of COVID-19; there is no approved treatment for this infectious disease, despite many efforts to develop therapeutic procedures for COVID-19. Emerging evidence shows that mesenchymal stromal/stem cell (MSC) therapy can be a suitable option for the management of COVID-19. These cells have many biological features (including the potential of differentiation, high safety and effectiveness, secretion of trophic factors and immunoregulatory features) that make them suitable for the treatment of various diseases. However, some studies have questioned the positive role of MSC therapy in the treatment of COVID-19. Accordingly, in this paper, we will focus on the therapeutic impacts of MSCs and their critical role in cytokine storm of COVID-19 patients.

Indexed as

Mesenchymal Stem Cell TransplantationCell CommunicationCOVID-19Cytokine Release SyndromeHumansMesenchymal Stem CellsSARS-CoV-2Toll-Like ReceptorsToll-Like Receptorscytokine stormimmunoregulatorymesenchymal stem cellnew coronavirus disease 2019pneumonia

Identifiers

PMID34545605
PMCPMC8652792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.